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Abstract:  Combined  curcumin  and  PS-341  treatment  has  been  reported  to  enhance 
cytotoxicity and minimize adverse effects through ERK and p38MAPK mechanisms in 
human multiple myeloma cells. However, whether JNK plays similar role in this process 
remains unclear. In the present study, we found combined treatment altered NF-κB p65 
expressions  and  distributions  in  multiple  myeloma  H929  cells.  Western  blot  analysis 
showed combined treatment inactivated NF-κB while activated JNK signaling. Pre-treatment 
with JNK inhibitor SP600125 could attenuate NF-κB inactivation and restored H929 cells’ 
survival. These results suggested that curcumin might enhance the cytotoxicity of PS-341 
by interacting with NF-κB, at least in part, through JNK mechanism. 
Keywords: curcumin; PS-341; multiple myeloma; NF-κB; JNK 
 
1. Introduction 
Multiple myeloma is a kind of plasma cell-derived human cancer that causes multiple bone lesions 
and  disturbs  the  production  of  normal  blood  cells.  It  is  the  second  most  prevalent  hematologic 
malignancy  after  non-Hodgkin’s  lymphoma  [1].  Complications  of  untreated  or  poorly  controlled 
multiple myeloma can be serious and it is generally thought to be an incurable disease, but remissions 
may be induced with steroids, chemotherapy,  radiotherapy, and stem cell transplants.  Bortezomib,  
(PS-341,  Velcade
®)  specifically  targeting  the  ubiquitin-proteasome  pathway,  is  the  first  defined 
therapeutic  proteasome  inhibitor  approved  by  FDA  for  treating  refractory,  advanced  or  rapidly 
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relapsed multiple myeloma [2]. It is well documented the mechanism of action for PS-341 lies in its 
highly affinity and specificity to the catalytic site of the 26S proteasome. There is also increasing 
evidence that the lethal actions of PS-341 may be related to inactivation of NF-κB pathway [3–5].  
PS-341  prevents  the  cleavage  of  the  inhibitors  of  NF-κBs  (IκBs)  proteins  and  interrupts  NF-κB 
translocation  from  the  cytoplasm  to  the  nucleus,  therefore  inhibiting  proliferation  and  inducing 
apoptosis [6]. Although PS-341 has been recommended as the first-line therapy for multiple myeloma, 
the  single-agent  activity  of  PS-341  has  been  limited  [7,8].  The  PS-341-based  clinical  therapeutic 
strategy  for  multiple  myeloma  usually  includes  other  chemotherapeutics,  such  as  adriamycin, 
decaspray, and thalidomide. 
Curcumin is a major active ingredient derived from the plant Curcuma longa L. Extensive studies 
during the past two decades have well documented a wide range of biological activities of curcumin, 
including  anti-cancer  properties.  Epidemiological  evidence  also  suggests  that  people  who  eat 
curcumin-rich  diets  have  a  lower  incidence  of  human  cancers.  It  is  noted  that  curcumin  induces  
down-regulation  of  NF-κB  through  suppression  of  IκBs,  leading  to  cancer  cell  apoptosis  [9–11]. 
Meanwhile, the chemosensitizing effect of curcumin has been reported in cancers of the breast, colon, 
pancreas, gut, liver, lung, prostate, brain, and in multiple myeloma, lymphoma and leukemia [12,13]. 
Interestingly, it is noted that curcumin shows a synergistic effect when combined with PS-341. We and 
others have recently reported that curcumin enhances the cytotoxic effect of PS-341 in human multiple 
myeloma  cells  through  regulating  NF-κB  and  Bcl-2  family  proteins  expressions  [14–17].  These 
beneficial  merits  develop  curcumin  as  a  potential  adjuvant  agent  to  standard  chemotherapy,  in 
particular for highly malignant, refractory, and relapsed cancers.  
Mitrogen-activated  protein  kinases  (MAPKs)  family  consists  of  extracellular  signal-regulated 
kinase (ERK), p38MAPK, and c-Jun NH2-terminal  kinase (JNK), which participated in  numerous 
physiological processes. Expanding studies indicate that ERK and p38MAPK signalings are implicated 
in  manipulating  NF-κB  and  its  downstream  targets  as  a  response  to  curcumin  in  human  multiple 
myeloma cells. However, the distinct roles of JNK in this process remain to be investigated [15,18,19]. 
To address these questions, we therefore explored potential roles of JNK in curcumin-mediated NF-κB 
signal in human multiple myeloma H929 cells. 
2. Results and Discussion 
2.1. Curcumin and PS-341 Altered Expression and Distribution Profiles of NF-κB p65 
NF-κB is  a dimer  mainly  composed of NF-κB p65 and NF-κB p50 subunits. Upon activation,  
NF-κB p65 was released from the NF-κB transcription complex, bound to corresponding DNA and 
regulated the transcription of specific genes. Therefore, NF-κB p65 is an inducible and functional 
subunit of NF-κB transcription complex, which provides the gene’s regulatory activities. NF-κB p65 in 
H929  cells  receiving  various  treatments  was  visualized  by  immunoflurencent  staining  (Figure  1).  
We observed that numerous H929 cells were NF-κB p65 positive and found that NF-κB p65 was 
distributed  in  the  whole  nucleus  (as  the  arrow  head  indicated).  The  proportions  of  NF-κB  
p65-expressing  cells  seemed  to  decrease  in  H929  cells  supplemented  with  curcumin  or  PS-341. 
Combined curcumin and PS-341 treatment notably decreased the amount of NF-κB p65 positive H929 Int. J. Mol. Sci. 2012, 13  4833 
 
 
cells  and  NF-κB  p65  green  fluorescent  density.  Notably,  NF-κB  p65  mainly  distributed  in  the 
periphery of the nucleus after combined treatment (as the arrow indicated).  
Figure 1. Immunoflurencent staining showing the expression and distribution of NF-κB 
p65 in response to curcumin with or without PS-341. Cell nucleus were stained with DAPI 
and visualized by blue fluorescence. NF-κB p65 was stained with corresponding antibodies 
and  visualized  by  green  fluorescence.  The  distribution  of  NF-κB  p65  within  the  cell 
nucleus was indicated by the arrow heads and arrows in the enlarged version. 
 
2.2. Curcumin and PS-341 Stabilized IκB through JNK Mechanism 
As the expressions and activities of NF-κB p65 are mainly regulated by IκB, Western blot was 
employed to analyze the content of IκB and NF-κB p65 after the indicated treatments. Incubation with 
curcumin or PS-341 for 24 h stabilized IκB and decreased NF-κB p65 content in H929 cells (Figure 2A). 
Combined treatment exerted a remarkable effect on the stabilization of IκB, which in turn inhibited the 
expression and transcription activities of NF-κB p65.  
ERK  and  p38MAPK  have  been  reported  to  contribute  to  curcumin-  and  PS-341-mediated  IκB 
stabilization and NF-κB expressions in human multiple myeloma cells in vivo and in vitro. Blockage of 
ERK and p38MAPK signaling restored NF-κB activation and promoted IκB degradation [15,18,19]. 
However, whether or not the JNK mechanism plays similar roles in the presence of curcumin and  
PS-341 is still unclear. We therefore investigated JNK expressions after the indicated treatment. As the 
activation of JNK requires phosphorylation (p-JNK), it was observed that treatment with curcumin or 
PS-341  singularly  did  not  significantly  affect  JNK  phosphorylation.  Similarly  to  previous  studies, 
combined curcumin and PS-341 treatment markedly promoted the expression of p-JNK compared with 
the baseline (Figure 2A). However, pre-treatment with the JNK specific inhibitor SP600125 attenuated 
NF-κB p65 inactivation and JNK phosphorylation (Figure 2B). Herein we raise the hypothesis that the 
mechanism of action for curcumin in combination with PS-341 treatment on NF-κB signaling might be 
JNK-dependent. Int. J. Mol. Sci. 2012, 13  4834 
 
 
Figure  2. Western blot analysis of  IκB, NF-κB p65, p-JNK and JNK. (A)  H929 cells 
received curcumin with or without PS-341 treatments. Combined treatment significantly 
activated JNK signaling and inhibited NF-κB activity; (B) Pretreatment with JNK inhibitor 
SP600125 inhibits JNK phosphorylation, and abolished effects of combined treatment on 
NF-κB activity. β-actin was used for equal loading.  
 
2.3. Blockage of JNK Restored H929 Cells Survival 
In order to  test  this idea, DAPI and PI fluorescent  stainings were performed to  determine cell 
viability and apoptosis. The blue fluorescence of DAPI represents the cell nucleus. Because PI cannot 
penetrate the livingcells, the PI fluorescence is only observed in the necrotic and dead cells. There 
were  few  PI  positive  H929  cells  without  curcumin  and  PS-341  treatment  (Figure  3).  However, 
combined curcumin and PS-341 treatment provoked remarkable H929 cell death compared with the 
baseline. As expected, pre-treatment with SP600125 decreased the numbers of PI positive cells. These 
results indicated that the JNK inhibitor SP600125 attenuated the cytotoxicity of combined treatment. 
Figure 3. DAPI and PI double staining of H929 cells. Cell nucleus was visualized by DAPI. 
Cells undergoing necrosis were stained by PI. Cells were observed at × 200 magnification, 
scale bar = 20 μm. 
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We next evaluated pre-treatment with SP600125 on H929 cells apoptosis by flow cytometry. Less 
than  2%  of  cells  underwent  apoptosis  without  any  treatments.  Combined  curcumin  and  PS-341 
treatment led to profound apoptotic cell death compared with the baseline. However, pre-treatment 
with SP600125 reduced the apoptotic ratio from (40.62 ±  4.619)% to (5.32 ±  1.155)%, suggesting 
combined treatment on the NF-κB signaling and H929 cells apoptosis was JNK-dependent (Figure 4). 
Figure 4. Flow cytometry analysis of cell apoptosis with or without SP600125 pre-treatment. 
* P < 0.05 vs. control or SP600125 pretreatment.  
 
3. Experimental Section  
3.1. Reagents 
Medicine: Curcumin was purchased from Sigma (St Louis, MO, USA). PS-341was purchased from 
Millennium  Pharmaceuticals  (Cambridge,  MA,  USA).  SP600125  was  purchased  from  Biomol 
Research Laboratories (Plymouth Meeting, PA). Curcumin, PS-341 and SP600125 were dissolved in 
DMSO  (1  mM)  as  stock  solutions,  stored  at  −20  ° C,  and  diluted  to  indicate  concentration  with  
culture medium. 
Materials:  Penicillin,  streptomycin,  fetal  bovine  serum  and  RPMI  1640  were  purchased  from 
Invitrogen (Carlsbad, CA, USA). Antibodies against IκB, NF-κB p65, JNK, p-JNK were purchased 
from Santa Cruz (Santa Cruz, CA, USA). Rabbit anti-β-actin antibody was purchased from Abcam 
(Cambridge, MA, USA).  
3.2. Cell Culture 
Human multiple myeloma H929 cells were obtained from American Type Culture Collection, and 
cultured in RPMI 1640 medium supplemented with 10% FBS, penicillin (100 U/mL) and streptomycin 
(100 μg/mL) in an atmosphere with 5% CO2 at 37 ° C. In all experiments, exponentially growing cells 
were used. 
3.3. Fluorescent Immunocytochemistry of NF-κB p65 
After  indicated  treatments,  cells  were  fixed  with  4%  paraformaldehyde  in  PBS  for  20  min  
and  permeabilized  with  0.5%  Trixon  X-100  for  15  min.  To  identify  the  cell  nucleus,  cells  were 
incubated with 10 μL DAPI. NF-κB p65 was visualized by incubation with rabbit anti-NF-κB p65 Int. J. Mol. Sci. 2012, 13  4836 
 
 
antibody  followed  by  corresponding  FITC-labeled  secondary  antibody.  Cells  were  then  viewed  
and  photographed.  DAPI  and  FITC  fluorescence  were  immediately  observed  under  a  fluorescent 
microscope (Olympus, Japan). 
3.4. Assay of IκB, NF-κB p65 and JNK 
IκB,  NF-κB  p65,  JNK  and  p-JNK  protein  contents  in  response  to  various  treatments  were 
determined by Western blot as described previously [14–17].  
3.5. Analysis of JNK in H929 Cell Apoptosis 
To  investigate  distinct  roles  of  JNK  in  combined  treatments  mediated  H929  cell  apoptosis, 
SP600125, a specific JNK inhibitor was used to block the phosphorous and activity of JNK. Cells were 
pre-treated with 5 μM SP600125 (SP600125 was not cytotoxic below 10 μM) for 1 h followed by 
combined curcumin and PS-341 treatment. JNK, p-JNK, IκB and NF-κB p65 protein contents were 
determined by Western blot as have described. For cell viability assay, H929 cells were stained by 
DAPI  and  PI.  The  necrotic  and  dead  H929  cells  were  observed  at  × 200  magnification  under  a 
fluorescent microscope (Olympus, Japan). Quantitatively analysis of cell apoptosis was determined by 
flow cytometry as have described. 
3.6. Statistical Analysis 
Data are expressed as means ±  SD. Differences between groups were analyzed by one-way analysis 
of variance (ANOVA) followed by LSD post hoc test using SPSS statistical software (SPSS, Inc., 
Chicago, IL). Significance was considered at * P < 0.05. 
4. Conclusion 
In the present study, we found that curcumin as a chemosensitizer could enhance the cytotoxic 
effect of PS-341. Combined curcumin and PS-341 treatment interacts with NF-κB signaling and alters  
NF-κB p65 expressions and distributions. Pre-treatment with JNK inhibitor SP600125 restored H929 
cells’ survival and attenuated NF-κB inactivation as a response to curcumin and PS-341. These results 
suggest the cytotoxic effect of combined treatment on H929 cells attributes to interaction with NF-κB 
signaling, and this mechanism might be partly JNK-dependent. 
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